Kineta Announces First Participant Dosed in Phase 1 Clinical Trial of KCP506, A Novel Non-Opioid for the Treatment of Chronic

Kineta Presents New Preclinical Data at ESMO Virtual Congress 2020 on its VISTA Antagonist Antibodies Seattle, WA — (December 9,

Kineta Presents New Preclinical Data at the 2020 SITC Annual Meeting on its VISTA Antagonist Antibodies Preclinical data demonstrates that

Kineta Presents New Preclinical Data on VISTA Antagonist Antibodies at AACR Conference on Tumor Immunology and Immunotherapy Seattle, WA —

Collaboration to advance a first-in-class α9/α10 nAchR antagonist for the treatment of chronic pain into Phase 1 clinical trials Seattle,

Kineta to Participate in BIO Investor Forum Digital Seattle, WA — (October 2, 2020) Kineta, Inc., a clinical stage biotechnology

Kineta Receives Regulatory Approval for Initiation of Phase 1 Clinical Trials of KCP506 First in-human clinical trials will evaluate the

Kineta Invited to Present at August 2020 Investor Conferences Seattle, WA — (July 30, 2020) Kineta, Inc., a clinical stage

Kineta Announces Formation of New Immuno-oncology Focused Scientific Advisory Board Seattle, WA — (April 21, 2020) Kineta, Inc., a clinical